APT-101 / APIE Therap - LARVOL DELTA

APIE Therapeutics Provides Evidence that Activating the Apelinergic System can Repair and Regenerate Lung Tissue Damaged by Pulmonary Fibrosis (GlobeNewswire) - "APIE Therapeutics...presented evidence that agonism of the apelinergic system (APJ/apelin axis) triggers the repair of damaged pulmonary vascular endothelial cells....APIE Tx is developing APT-101, a small molecule designed to bind selectively and preferentially to APJ, for the treatment of fibrotic diseases such as systemic sclerosis-associated lung disease (SSc-ILD) and idiopathic pulmonary fibrosis (IPF). APT-101 was granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of IPF."

Orphan drug • Preclinical • Idiopathic Pulmonary Fibrosis • Interstitial Lung Disease • Systemic Sclerosis

APIE Therapeutics Presented Preclinical Findings Supporting Activation of the Apelin Receptor as a Therapeutic Approach for Systemic Sclerosis (GlobeNewswire) - " APIE Therapeutics, a preclinical pharmaceutical company pioneering novel and proprietary anti-fibrotic drugs that target the apelin receptor (APJ), presented results from in vitro and in vivo studies supporting the potential of APT-101 as a therapeutic for interstitial lung disease (ILD), including those cases associated with systemic sclerosis (SSc-ILD). APT-101 is an orally bioavailable small molecule that selectively and potently targets and activates APJ, thus acting upstream of factors that promote fibrosis, representing a potentially disease-modifying approach. It is in preclinical development for the treatment of SSc-ILD and idiopathic pulmonary fibrosis (IPF)."

Preclinical • Idiopathic Pulmonary Fibrosis